7-ethyl-10-hydroxycamptothecin Completed Phase 2 Trials for Triple Negative Breast Cancer (TNBC) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00951054A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer